Document text
Principal Investigator: JANICE CHOU
Organization: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
Fiscal Year: 2023
Award: $1,942,202
Funding agency: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Clinically, GSD-Ib patients manifest a metabolic phenotype of impaired blood glucose homeostasis and a long-term risk of hepatocellular adenoma/carcinoma (HCA/HCC). The etiology of HCA/HCC in GSD-Ib is unknown. Studies have shown that deficiency in autophagy, an evolutionary conserved, degradative process that produces energy and building blocks through lysosomal degradation of intracellular proteins and organelles in times of nutrient deprivation and environmental stresses, contributes to hepatocarcinogenesis. Autophagy can be regulated positively by sirtuin 1 (SIRT1), AMP-activated protein kinase (AMPK), and forkhead box O (FoxO) transcription factor family members. In the liver, AMPK is activated via phosphorylation of the AMPK -subunit at residue T172 by the liver kinase B-1 (LKB1), a serine/threonine kinase. To understand the pathways contributing to hepatocarcinogenesis in GSD-Ib, we hypothesized that impaired hepatic autophagy is a significant contributor. In this study, we show that G6PT deficiency leads to impaired hepatic autophagy evident from attenuated expression of many components of the autophagy network, decreased autophagosome formation, and reduced autophagy flux. The G6PT-deficient liver displayed impaired SIRT1 and AMPK signaling, along with reduced expression of SIRT1, FoxO3a, LKB1, and the active p-AMPK. Importantly, we show that overexpression of either SIRT1 or LKB1 in G6PT-deficient liver restored autophagy and SIRT1/FoxO3a and LKB1/AMPK signaling. The hepatosteatosis in G6PT-deficient liver decreased SIRT1 expression. LKB1 overexpression reduced hepatic triglycerides levels, providing a potential link between LKB1/AMPK signaling upregulation and the increase in SIRT1 expression. In conclusion, downregulation of SIRT1/FoxO3a and LKB1/AMPK signaling underlies impaired hepatic autophagy which may contribute to HCA/HCC development in GSD-Ib. Understanding this mechanism may guide future therapies.
GSD-Ia is a pediatric genetic disorder. The rAAV-G6PC vector used in Phase III clinical trial for GSD-Ia (NCT05139316) is episomally expressed. Currently, there is insufficient clinical data to understand if multi-decade episomal transgene expression can be maintained in the human liver at a therapeutic level. We therefore explored alternative genetic technologies for GSD-Ia therapy, such as CRISPR/Cas9-based gene editing. We previously generated a G6pc-R83C mouse strain carrying the prevalent pathogenic G6PC-p.R83C variant and showed that the G6pc-R83C mice exhibit the pathophysiology of impaired glucose homeostasis mimicking human GSD-Ia. In an initial exploration of CRISP/Cas-9-based editing using AAV to deliver the CRISPR reagents, we showed that a homology directed repair strategy could correct the abnormal metabolic phenotype of neonatal G6pc-R83C mice. Using the G6pc-R83C mice, we now explored a CRISPR/Cas9-based double-strand DNA oligonucleotide (dsODN) insertional strategy that uses the non-homologous end joining repair mechanism to correct the pathogenic p.R83C variant in G6pc exon-2. The strategy is based on the insertion of a short dsODN into G6pc exon-2 to disrupt the native exon, and to introduce an additional splice acceptor site and the correcting sequence. When transcribed and spliced the edited gene would generate a wild-type mRNA encoding the native G6Pase- protein. The editing reagents formulated in lipid nanoparticles (LNP) were delivered to the liver. Mice were treated either with one dose of LNP-dsODN at age 4 weeks or with 2 doses of LNP-dsODN at age 2 and 4 weeks. The G6pc-R83C mice receiving successful editing expressed 4% of normal hepatic G6Pase- activity, maintained glucose homeostasis, lacked hypoglycemic seizures, and displayed normalized blood metabolite profile. The outcomes are consistent with preclinical studies supporting previous gene augmentation therapy which is currently in clinical trials. This editing strategy may offer the basis for a therapeutic approach with an earlier clinical intervention than gene augmentation, with the additional benefit of a potentially permanent correction of the GSD-Ia phenotype.
Renal disease is a serious long-term complication for GSD-Ia. The early kidney manifestations of GSD-Ia are impaired renal gluconeogenesis, and nephromegaly caused by increased glycogen accumulation. The only therapies currently available to treat GSD-Ia are dietary therapies which have significantly alleviated metabolic abnormalities but only delay the onset of chronic kidney disease. The underlying pathological processes remain uncorrected, and glomerular hyperfiltration, hypercalciuria, hypocitraturia and urinary albumin excretion still occur in metabolically compensated GSD-Ia patients. We have previously shown that one mechanism underlies GSD-Ia nephropathy is fibrosis mediated by activation of the renin-angiotensin system (RAS).
The Wnt/-catenin signaling regulates the expression of a variety of downstream mediators implicated in renal fibrosis, including multiple genes in the RAS. Sustained activation of Wnt/-catenin signaling is associated with the development and progression of renal fibrotic lesions that can lead to chronic kidney disease. In this study, we examined the molecular mechanism underlying GSD-Ia nephropathy. Damage to the kidney proximal tubules is known to trigger acute kidney injury (AKI) that can, in turn, activate Wnt/-catenin signaling. We show that GSD-Ia mice display AKI that leads to activation of the Wnt/-catenin/RAS axis. Renal fibrosis was demonstrated by increased renal levels of Snail1, -smooth muscle actin (-SMA), and extracellular matrix proteins, including collagen-I1 and collagen-IV. Treating GSD-Ia mice with a CBP/-catenin inhibitor, ICG-001, significantly decreased nuclear translocated active -catenin and reduced renal levels of renin, Snail1, -SMA, and collagen-IV. The results suggest that inhibition of Wnt/-catenin signaling may be a promising therapeutic strategy for GSD-Ia nephropathy.
We explore the Adenine base editor (ABE)-based technologies that enable a programmable conversion of AT to GC in genomic DNA for GSD-Ia therapy. The ABE system works in both dividing and non-dividing cells, is reported to produce virtually no indels or off-target editing in the genome, can correct a pathogenic variant in its native genetic locus, leading to permanent, therapeutically effective long-term expression. This is a collaborative study with Beam Therapeutics, Cambridge, MA under a CRADA.
The G6PC-p.R83C is the most prevalent pathogenic mutation identified in Caucasian GSD-Ia patients that contains a single G>A transition in the G6PC gene. We first generated a homozygous humanized R83C/R83C mouse strain, the G6PC-R83C mouse by inserting the entire coding sequence of the human G6PC-p.R83C along with human G6PC 3-UTR into exon 1 of the mouse G6pc gene at the ATG start codon. This insertion places the human transcript under the control of the native mouse G6pc promoter/enhancer. The mouse G6pc gene is disrupted by a premature STOP codon created in the mouse G6pc exon 1. We showed that the G6PC-R83C mice manifest impaired glucose homeostasis characterized by growth retardation, hypoglycemia, hyperlipidemia, hyperuricemia, hepatomegaly, and nephromegaly mimicking the abnormal metabolic phenotype of human GSD-Ia. We then treated newborn G6PC-R83C mice with lipid nanoparticles (LNP) encompassing the guide RNA and mRNA encoding ABE (LNP-ABE) and showed that the treated mice grew normally to age 8 weeks without hypoglycemia seizures. The LNP-ABE-treated G6PC-R83C mice expressed significant levels of hepatic G6Pase- activity with an editing efficiency up to 60% and displayed normalized blood metabolite profiles and could tolerate 24 hours of fasting. Taken together, our data demonstrate the potential of base-editing to correct the G6PC-p.R83C mutation in
Terms: <(hydroxymethylglutaryl-CoA reductase (NADPH)) kinase><0-4 weeks old><1H-Purin-6-amine><3' Splice Site><5'-AMP-activated protein kinase><AAV vector><AMP-activated kinase><AMP-activated protein kinase><AMPK enzyme><Actins><Active Sites><Acute Renal Failure with Renal Papillary Necrosis><Adenine><Age><Albumins><Angiotensin-Forming Enzyme><Angiotensinogenase><Animal Model><Animal Models and Related Studies><Attenuated><Autophagocytosis><Autophagosome><Autoregulation><Basal Transcription Factor><Basal transcription factor genes><Benign Hepatoma><Blood><Blood Glucose><Blood Reticuloendothelial System><Blood Sugar><CRADA><CRISPR><CRISPR approach><CRISPR based approach><CRISPR based therapeutics><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR therapeutics><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas therapeutics><CRISPR/Cas9><CRISPR/Cas9 technology><CRISPR/Cas9 therapeutics><CRISPR/Cas9 therapy><Carcinoma><Cas nuclease technology><Cas9 based therapeutics><Caucasian><Caucasian Race><Caucasians><Caucasoid><Caucasoid Race><Causality><Cell Communication and Signaling><Cell Signaling><Childhood><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical><Clinical Data><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats based therapeutics><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Clustered Regularly Interspaced Short Palindromic Repeats therapeutics><Code><Coding System><Collaborations><Collagen><Collagen IV><Collagen Type IV><Compensation><Complex><Complication><Cooperative Research and Development Agreement><Couples><Cytoplasm><D-Glucose><D-Glucose-6-phosphate phosphohydrolase><DNA Therapy><Data><Development><Dextrose><Diet therapy><Disease><Disorder><Dose><Double-Stranded DNA><Down-Regulation><Dysfunction><Endoplasmic Reticulum><Enhancers><Enlarged Liver><Epithelial cancer><Ergastoplasm><Etiology><Excretory function><Exhibits><Exons><Extracellular Matrix Proteins><Face><Family member><Fasting><Fatty Liver><Fibrosis><Functional disorder><Future><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic Alteration><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic Transcription><Genetic defect><Genome><Genomic DNA><Gierke's Disease><Gluconeogenesis><Glucose><Glucose-6-Phosphatase Deficiency><Glucose-6-Phosphate><Glucose-6-Phosphate Phosphohydrolase><Glucosephosphatase Deficiency><Glycogen><Glycogen Storage Disease Type I><Glycogen storage disease type Ia><Glycogenosis 1><Goals><Growth><Guide RNA><HMG CoA reductase (NADPH) kinase><HMG CoA reductase kinase><HMG coenzyme A reductase (NADPH) kinase><Hepatic><Hepatocarcinogenesis><Hepatocellular Adenoma><Hepatomegaly><Hepatorenal Glycogen Storage Disease><Heritability><Homeostasis><Hour><Human><Hydrolysis><Hyperlipemia><Hyperlipidemia><Hyperuricemia><Hypoglycemia><Impairment><Initiation Codon><Initiator Codon><Inorganic Phosphate Transporter><Integral Membrane Protein><Interphase Cell><Intestinal><Intestines><Intracellular Communication and Signaling><Intrinsic Membrane Protein><Involuntary Muscle><Kidney><Kidney Diseases><Kidney Urinary System><Kinases><L-Serine><Laboratories><Legal patent><Lesion><Licensing><Link><Liver><Liver Carcinogenesis><Liver Cell Adenoma><Liver Steatosis><Malignant Epithelial Neoplasms><Malignant Epithelial Tumors><Mediating><Mediator><Messenger RNA><Metabolic><Mice><Mice Mammals><Modern Man><Molecular><Molecular Genetics><Mouse Strains><Murine><Mus><Mutation><NHEJ><Neonatal><Nephropathy><Newborn Infant><Newborns><Non-Homologous End Joining><Non-dividing Cell><Non-homologous DNA End Joining><Nondividing Cell><Nonhomologous DNA End Joining><Nonhomologous End Joining><Nonsense Codon><Nuclear Translocation><Occidental><Oligo><Oligonucleotides><Organelles><Outcome><Patents><Pathogenicity><Pathologic Processes><Pathological Processes><Pathway interactions><Patients><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phase><Phase 1/2 Clinical Trial><Phase 3 Clinical Trials><Phase I/II Clinical Trial><Phase III Clinical Trials><Phenotype><Phosphate Transport Proteins><Phosphate Transporters><Phosphates><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Physiological Homeostasis><Physiopathology><Premature Stop Codon><Process><Protein Phosphorylation><Protein-Serine Kinase><Protein-Serine-Threonine Kinases><Protein-Threonine Kinase><Proteins><Proximal Kidney Tubules><RNA Expression><RNA Splicing><Reagent><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Renal Disease><Renin><Renin-Angiotensin System><Reporting><Resting Cell><Risk><SIRT1><SIRT1 gene><Seizures><Serine><Serine Kinase><Serine-Threonine Kinases><Serine/Threonine Protein Kinase Gene><Signal Transduction><Signal Transduction Systems><Signaling><Sirtuin 1><Smooth Muscle><Snails><Splice Acceptor Sites><Splicing><Start Codon><System><Technology><Therapeutic><Threonine Kinase><Tissue Growth><Transcript><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transmembrane Protein><Transmembrane Protein Gene><Transphosphorylases><Triacylglycerol><Triglycerides><Type IV (Basement Membrane) Collagen><UTRs><Untranslated Regions><Up-Regulation><Upregulation><Variant><Variation><Vitamin B4><Von Gierke's Disease><Work><acute kidney injury><adeno-associated viral vector><adeno-associated virus vector><ages><attenuate><attenuates><autophagy><base editing><base editor><biological signal transduction><blood glucose regulation><bowel><carcinogenesis in the liver><causation><chronic kidney disease><damage to kidney><determine efficacy><developmental><dietary therapy><disease causation><ds-DNA><dsDNA><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><environmental stresses><environmental stressor><epithelial carcinoma><evaluate efficacy><examine efficacy><excretion><faces><facial><fasted><fasts><gDNA><gRNA><gene augmentation intervention><gene augmentation therapy><gene corrected><gene correction><gene locus><gene repair therapy><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic locus><genetic technology><genetic therapy><genome mutation><genomic location><genomic locus><genomic therapy><glucose RA><glucose biosynthesis><glucose control><glucose homeostasis><glucose production><glucose rate of appearance><glucose regulation><glucose-6-phosphatase><glycogenosis type I><hepatic body system><hepatic carcinogenesis><hepatic organ system><hepatic steatosis><hepatocellular carcinogenesis><hepatorenal glycogenosis><hepatosteatosis><hydroxymethylglutaryl-CoA-reductase kinase><hypercalcinuria><hypercalciuria><hypercalciuric><hypoglycemic><hypoglycemic episodes><indel><inhibitor><inorganic phosphate><insertion-deletion><insertion-deletion mutation><insertion/deletion><insertion/deletion mutation><kidney damage><kidney disorder><kidney fibrosis><lipid based nanoparticle><lipid nanoparticle><liver cancer pathogenesis><liver tumorigenesis><mRNA><metabolic phenotype><metabotype><model of animal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><newborn child><newborn children><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><nutrient deprivation><nutritional deprivation><oligos><ontogeny><overexpress><overexpression><pathophysiology><pathway><pediatric><pharmaceutical><phase III protocol><pre-clinical study><preclinical study><promoter><promotor><rAAV><recombinant AAV><renal><renal damage><renal disorder><renal fibrosis><renal proximal tubule><repair><repair strategy><repaired><therapeutically effective><transcription factor><transgene expression><uricacidemia><urinary><vector><virtual><white race>